Back to Search Start Over

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer.

Authors :
Elghazaly H
Rugo HS
Azim HA
Swain SM
Arun B
Aapro M
Perez EA
Anderson BO
Penault-Llorca F
Conte P
El Saghir NS
Yip CH
Ghosn M
Poortmans P
Shehata MA
Giuliano AE
Leung JWT
Guarneri V
Gligorov J
Gulluoglu BM
Abdel Aziz H
Frolova M
Sabry M
Balch CM
Orecchia R
El-Zawahry HM
Al-Sukhun S
Abdel Karim K
Kandil A
Paltuev RM
Foheidi M
El-Shinawi M
ElMahdy M
Abulkhair O
Yang W
Aref AT
Bakkach J
Bahie Eldin N
Elghazawy H
Source :
Cancers [Cancers (Basel)] 2021 May 08; Vol. 13 (9). Date of Electronic Publication: 2021 May 08.
Publication Year :
2021

Abstract

Background : The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods : A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion : These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

Details

Language :
English
ISSN :
2072-6694
Volume :
13
Issue :
9
Database :
MEDLINE
Journal :
Cancers
Publication Type :
Academic Journal
Accession number :
34066769
Full Text :
https://doi.org/10.3390/cancers13092262